Company News

AusBiotech CEO Rebekah Cassidy said, “For our sector to thrive, it needs a coordinated and well-invested research sector. Without research, there is no pipeline of health innovation, no pipeline of companies, and no ecosystem to sustain them.”

Immuron (ASX:IMC) has closed the financial year 2025 with record sales and significant progress across its clinical programs, positioning the company for another pivotal year ahead.

Island Pharmaceuticals (ASX:ILA) has declared the financial year 2025 as defining, having delivered encouraging trial results for its dengue program and acquired a second antiviral asset, which positions the company as a dual-asset player in global infectious diseases.

Prescient Therapeutics (ASX:PTX) has secured fresh backing from investors, completing a $3 million capital raise to support the clinical development of its targeted cancer therapy PTX-100.

OncoSil Medical (ASX:OSL) has capped a significant year with major regulatory approvals, clinical trial progress, and expanding commercial traction for its brachytherapy device in pancreatic cancer.

Neurotech International (ASX: NTI) has reported a year of significant clinical achievements, regulatory recognition, and corporate renewal as it advances its proprietary cannabinoid therapy, NTI164, for paediatric neurological disorders.

Paradigm Biopharmaceuticals (ASX:PAR) has marked 2025 as a transformative year, moving from regulatory preparation to the active execution of its global Phase 3 clinical trial for iPPS (Zilosul) in knee osteoarthritis, while also strengthening its financial foundations and broadening its treatment pipeline.

Adherium (ASX:ADR) is positioning itself for the future as a data-driven respiratory monitoring company, reporting progress in its US expansion and a pivot toward commercialisation.

Cyclopharm (ASX:CYC) has posted its strongest half-year performance on record, underpinned by accelerating adoption of its Technegas technology in the US, robust international sales, and fresh intellectual property milestones that extend the company’s growth runway.

Cartherics, the Melbourne-based biotechnology company developing off-the-shelf immune cell therapies for high-impact women’s diseases, has strengthened its intellectual property portfolio with the grant of a new Chinese patent.

Starpharma Holdings (ASX:SPL) has delivered a year of strategic focus and scientific progress, sharpening its efforts to extract long-term value from its proprietary dendrimer technology platform while strengthening its commercial foundations across oncology, women’s health and antiviral products.

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications.